Le Lézard
Classified in: Health, Science and technology
Subject: FEA

Alligator Bioscience receives patent approval for the drug candidate ATOR-1015


LUND, Sweden, Sept. 16, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,774,150 which covers compositions of matter directed to Alligator's bispecific drug candidate ATOR-1015. The granted patent's earliest expiry year is 2036.

"ATOR-1015 constitutes a new concept, a tumor-localizing bispecific CTLA-4 antibody. Our invention addresses one of the key challenges within immuno-oncology, i.e. the narrow therapeutic window of CTLA-4 drugs. This is now protected by a granted US patent," commented Per Norlén, CEO at Alligator Bioscience.

ATOR-1015 is developed for the treatment of metastatic cancer. Promising safety data from the ongoing ATOR-1015 Phase I clinical study was presented at ASCO in June 2020. The Phase I dose escalation study is planned to be completed during the fourth quarter 2020 and the subsequent Phase Ib efficacy study in malignant melanoma is due to start in 2021.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on September 16, 2020.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes five lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/alligator-bioscience/r/alligator-bioscience-receives-patent-approval-for-the-drug-candidate-ator-1015,c3194695

The following files are available for download:

https://mb.cision.com/Main/12681/3194695/1306686.pdf

Alligator Bioscience receives patent approval for the drug candidate ATOR-1015

 

SOURCE Alligator Bioscience


These press releases may also interest you

at 10:20
Sound Pharmaceuticals' IND Involving Cochlear Implantation Allowed by the FDA
Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI). The goal of this Phase 2 SPI-1005...

at 10:20
SecurityScorecard Recognized as a Leader in Cybersecurity Risk Ratings Report
SecurityScorecard has been named a leader in The Forrester WaveTM: Cybersecurity Risk Ratings Platforms, Q2 2024. The report covers 10 vendors with cybersecurity risk ratings capabilities. SecurityScorecard received the highest score possible across...

at 10:19
ClearBlade & SAS have been positioned as the leaders in the 2024 SPARK Matrixtm for the global Internet of Things (IoT) Edge Analytics platform market by Quadrant Knowledge Solutions
Shared market leadership underscores strong partnership in Edge AI applications The Quadrant Knowledge Solutions SPARK Matrixtm provides competitive analysis and ranking of the leading Internet of Things (IoT) edge analytics platform...

at 10:16
Packaging Automation Market to be Worth $118.8 Billion by 2031 - Exclusive Report by Meticulous Research®
According to a new market research report titled, 'Packaging Automation Market by Offering (Solution, Services), Type, End-use Industry (Healthcare & Pharmaceuticals, E-commerce & Logistics, Food & Beverage, Chemical & Refinery, Aerospace & Defense),...

at 10:15
Inverness Graham Announces the Sale of Swipeclock
Inverness Graham ("IGI"), a Philadelphia based buyout firm that acquires innovative companies where technology is transforming traditional industry, is pleased to announce the sale of Swipeclock, a leading provider of cloud-based integrated human...

at 10:15
Smart Learning Market worth $155.2 billion by 2029 - Exclusive Report by MarketsandMarketstm
AI, VR/AR, and EdTech developments will power smart learning in the future by allowing individualized, immersive, and adaptable learning opportunities. Prioritizing lifelong learning, online and hybrid learning, and data security will increase global...

More news about Science and technology...


News published on and distributed by: